Ipratropiumbromide Sandoz

Ipratropium bromide, the active ingredient in Ipratropiumbromide Sandoz, is an anticholinergic (muscarinic antagonist) presented as an inhalation formulation for inhalation use. It treats chronic obstructive pulmonary disease and asthma as add‑on therapy in adult patients. GNH USA supplies Ipratropiumbromide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide acts on the muscarinic receptors of the airway smooth muscle to provide bronchodilation in obstructive lung diseases. - Chronic obstructive pulmonary disease (COPD): improves airflow and reduces the frequency of exacerbations. - Asthma (add‑on therapy): provides additional bronchodilation when used with other asthma medications. - Chronic bronchitis: alleviates bronchial constriction and helps ease coughing associated with mucus hypersecretion.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth - Cough - Throat irritation - Headache

Serious or Rare Side Effects: - Paradoxical bronchospasm - Angioedema - Urinary retention

Before prescribing Ipratropium bromide, clinicians should consider several safety aspects. - Assess respiratory status before initiation: evaluate severity of COPD or asthma. - Monitor for anticholinergic effects: watch for dry mouth, urinary retention, or constipation. - Use with caution in patients with narrow‑angle glaucoma: may increase intra‑ocular pressure. - Avoid in patients with known hypersensitivity to ipratropium or atropine derivatives. - Store at room temperature below 25 °C: keep in original container, protect from light and moisture.

Ipratropium bromide can interact with other medications, requiring attention to potential additive effects.

Major Interactions (Avoid): - Concurrent use with other muscarinic antagonists (e.g., tiotropium): may increase anticholinergic burden. - Use with ophthalmic anticholinergics in glaucoma patients: risk of heightened intra‑ocular pressure.

Moderate Interactions (Monitor Closely): - Combination with β2‑agonists: may enhance bronchodilation, monitor heart rate. - Use with diuretics: may exacerbate dry mouth. - Concurrent antihistamines: may increase anticholinergic side‑effects.